Bypassing the Blood-Brain Barrier

Impacting the lives of millions of neurodegenerative disease patients through next-generation medtech.

Through our groundbreaking drug delivery technology and specialty-drug formulations, we are striving to improve the quality of life for patients suffering from debilitating diseases such as Alzheimer’s, Parkinson’s, mild cognitive impairment, and multiple sclerosis.

Our patented Controlled Particle Dispersion (CPD)® technology is designed to address the most challenging step of treating CNS disorders — getting medication to targeted areas of the brain. In preliminary studies, Kurve’s CPD® technology has been shown to bypass the blood-brain barrier (BBB) and deliver up to 30x more medication directly to the brain than infusions.

Why Invest?

Headquartered in Lynnwood, WA, Kurve is at the forefront of a new era of central nervous system (CNS) disorder treatments.

What does an investment in Kurve Therapeutics mean?

Help millions of people

1 in 6 people — over one billion people — suffer from neurological disorders.

Every 3 seconds, someone in the world develops dementia.

Impact a vast market

The market size for dementia alone is $1.3 trillion.

If dementia was a country, it would be the 14th-largest economy in the world.

Reshape the medical field

Our mission is to revolutionize the treatment landscape of CNS disorders, bringing new hope to those suffering with limited treatment options.

Disrupt a Multi-Billion-Dollar Market

The market size for CNS disorders, including mild cognitive aging and Alzheimer’s disease, is substantial and rapidly growing as the population ages. There are 121 million people over the age of 50 in the United States alone who make up the cognitive aging market.

Alzheimer’s disease is one of the costliest diseases in the nation. In 2020 alone, there was a $257 billion loss in productivity by family and friends providing unpaid care to people suffering from the disease. Coupled with the total national cost of caring for people living with Alzheimer’s and other dementias ($355 billion in 2021), the total economic cost of caring for Alzheimer’s patients exceeds $600 billion annually.

With the number of people suffering from the disease set to increase by 22% by 2025, there is a dire global need for efficient treatments.

$50M

Total
Filing Raise

$580

Minimum
Investment

$5.80

Price
Per Share

30-Day Bonus Program

Kurve’s Regulation A+ Offering includes an exclusive bonus program!

Investors will be eligible to receive additional shares of common stock (“Bonus Shares”) depending upon the amount invested by such investors.

Here’s the breakdown:

First 30 Days of Offering

15% bonus shares for investments less than $100,000

We will offer a 15% bonus in the form of bonus shares for investors who invest less than $100,000 within the first thirty (30) days following qualification of the offering (not including the date on which the offering is qualified).

First 30 Days of Offering

30% bonus shares for investments over $100,000

We will offer a 30% bonus in the form of bonus shares for investors who invest more than $100,000 within the first thirty (30) days following qualification of the offering (not including the date on which the offering is qualified).

After First 30 Days of Offering

20% bonus shares for investments over $100,000

We will offer a 20% bonus in the form of bonus shares for investors who invest more than $100,000 after the first thirty (30) days following qualification of the offering (not including the date on which the offering is qualified).

Kurve Therapeutics will absorb the cost of the issuance of the Bonus Shares; to the extent any are issued, it will reduce the Proceeds that the Company receives. The issuance of these Bonus Shares will have a maximum potential dilutive effect of 28,735,632 Shares.

Next-Generation Medtech

ViaNase™: Intelligent Delivery, the Future of CNS Treatments

Kurve offers a new, disease-modifying approach to treating CNS disorders with our patented Controlled Particle Dispersion (CPD)® technology. Our advanced technology creates a precisely-controlled turbulent flow, designed to allow a larger portion of disease-modifying formulations to be delivered to targeted areas of the brain with precise dosage control. Traditional intranasal delivery methods such as nasal sprays cannot access the blood-brain barrier, leaving the majority of the medication in the nasal cavity, sinuses, or GI tract.

Our medtech innovation features:

Phase III Ready

Our technology’s success in clinical trials thus far, coupled with our Phase-III-ready status, offers a unique opportunity to be a part of revolutionizing the treatment of CNS disorders.

We are currently ready for Phase III clinical trials in three separate disease states, and are one Phase III study away from being eligible for FDA approval. Approximately 75% of treatments entering clinical trials do not make it to Phase III.

More than 15 human-use clinical trials with our technology have been conducted so far, for which our next-generation technology was the device of choice.

Clinical trials using Kurve’s Controlled Particle Dispersion® technology include studies conducted by:

Johns Hopkins School of Medicine

Harvard Medical
School

United States of America Department of Defense

Icahn School of Medicine at Mount Sinai

University of Massachusetts Amherst

Wake Forest
University

Shankle
Clinic

Featured in 18 peer-reviewed publications by leading institutes such as:

Kurve is at the forefront of a new era of central nervous system disorder treatments.

Medtech Innovators

Meet the team behind the breakthrough.

Marc Giroux

Chairman & Chief
Executive Officer

As a serial entrepreneur and founder of five companies, Marc Giroux has closed agreements with global industry-leading pharmaceutical companies — including four of the top 20 international firms.

Glenn Cornett, M.D., Ph.D.

Chief Science
Officer

Biotech entrepreneur and advisor Dr. Cornett has a long, proven history of creating exponential growth within biotech companies.

Tom S. McDowell

Chief
Operating Officer

An accomplished and highly regarded COO, Tom McDowell excels at creating organized, functional accounting structures, serving as a stabilizing force and contributing to the growth of a number of businesses across multiple industries.

Kurve Therapeutics Timeline & Milestones

Not ready to invest yet?

Subscribe to Stay Up to Date

Download Our Investor Materials

The Investor Materials PDF will be emailed to you.

View the Offering Circular at https://kurvetx.com/offering-circular